Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

NUVBBullishIndustry Newsnews

High materiality8/10

NUVB to present expanded safusidenib data at SNO, highlighting IDH1 glioma potential

Nov 2, 2026, 8:15 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Upcoming SNO data readouts and Fast Track designation support upside potential; positive durability signals could re-rate the stock, though concrete data are not yet disclosed.

AI summary

What happened, with direct paths to the underlying reporting

Nuvation Bio will showcase expanded safusidenib data at the Society for Neuro-Oncology meeting in November, including updated Phase 2 J201 results and three ongoing-study posters. The event also highlights the Phase 3 SIGMA maintenance trial and exploratory cohorts, underscoring a broader safusidenib development program. Positive durability signals and FDA Fast Track designation could catalyze near-term sentiment, depending on data depth and safety profiles.

NUVB to present four safusidenib posters at SNO Annual Meeting in Philadelphia (Nov 12–15, 2026).
Phase 2 J201 data updated; additional data beyond July topline results will be shown.
SIGMA Phase 3 maintenance trial after RT/CRT and adjuvant TMZ; ~300 patients.
Exploratory cohorts: oligodendroglioma and post-vorasidenib progression; publications later.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

NUVB to present expanded safusidenib data at SNO, highlighting IDH1 glioma potential

Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate